Clinical Trial Update: Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on SOM230 LAR for reducing tumor size in primary inoperable thymoma and/or locally recurrent thymoma; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymoma

Drugs mentioned

• SOM230 LAR (somatostatin analog? (SOM230 LAR))

Snippet

Sponsor: Prof. Dr. Berthold Schalke | Conditions: Primary Inoperable Thymoma, Local Recurrent Thymoma | Phase 2 | Status: COMPLETED | Results posted: 2018-02-05